Weiss Ratings Reiterates Sell (D-) Rating for Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC)

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC)‘s stock had its “sell (d-)” rating reaffirmed by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Oaktree Acquisition Corp. III Life Sciences Price Performance

Oaktree Acquisition Corp. III Life Sciences stock opened at $10.62 on Friday. The company’s fifty day moving average price is $10.50 and its 200 day moving average price is $10.44. Oaktree Acquisition Corp. III Life Sciences has a 1 year low of $9.95 and a 1 year high of $10.85.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Clear Street LLC grew its stake in Oaktree Acquisition Corp. III Life Sciences by 265.1% in the 2nd quarter. Clear Street LLC now owns 22,000 shares of the company’s stock valued at $230,000 after acquiring an additional 15,975 shares during the period. Meteora Capital LLC acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth $517,000. Kepos Capital LP acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth $563,000. Picton Mahoney Asset Management acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth $767,000. Finally, Radcliffe Capital Management L.P. acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth $856,000.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.